Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess whether prophylactic therapy with an activated
prothrombin complex concentrate (FEIBA)will result in a significant reduction in the number
of bleeds in patients with hemophilia and persistent high responding inhibitors.